Given the up-regulation of STING expression induced by the SGLT2 inhibitor, we also found that the combined treatment with SGLT2 inhibitor and 2’3’-cGAMP further promoted the infiltration of CD4+ and CD8+ T cells, exerting synergistic antitumor effects in osteosarcoma. Here, SLC5A2 is linked to osteosarcoma.